Ovarian Cancer Drug Reduces Progression
In a recent clinical trial, an ovarian cancer drug called Lynparza significantly reduced the risk for disease progression. This medication belongs to a class of drugs called PARP—poly (ADP-ribose) polymerase—inhibitors, a type of targeted therapy that may prevent cancer cells from repairing damaged DNA, causing them to die. PARP inhibitors are also being studied to treat breast cancer and pancreatic cancer.
Clinical trial participants with recurrent ovarian cancer who were given Lynparza lived an average of 19.1 months without disease progression–30.2 months when progression was measured by central, blinded review. Those given a placebo lived about 5.5 months without worsening disease.
Lynparza was approved by the U.S. Food and Drug Administration in 2014. It is currently recommended as a fourth-line treatment for ovarian cancer. The goal of this recent clinical trial is to move the drug to a second-line therapy.
Image Credit: Thinkstock